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Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and
microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ
inhibitor, showed antitumor activity in patients with previously treated indolent
non-Hodgkin’s lymphomas.

This article was published on January 22,
2014, at NEJM.org.

In this single-group, open-label, phase 2 study, 125 patients with indolent non-Hodgkin’s lymphomas who had not had a response to rituximab and an alkylating agent or
had had a relapse within 6 months after receipt of those therapies were administered
idelalisib, 150 mg twice daily, until the disease progressed or the patient withdrew
from the study. The primary end point was the overall rate of response; secondary end
points included the duration of response, progression-free survival, and safety.
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DOI: 10.1056/NEJMoa1314583
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Methods

Results

The median age of the patients was 64 years (range, 33 to 87); patients had received
a median of four prior therapies (range, 2 to 12). Subtypes of indolent non-Hodgkin’s
lymphoma included follicular lymphoma (72 patients), small lymphocytic lymphoma
(28), marginal-zone lymphoma (15), and lymphoplasmacytic lymphoma with or without Waldenström’s macroglobulinemia (10). The response rate was 57% (71 of 125
patients), with 6% meeting the criteria for a complete response. The median time to
a response was 1.9 months, the median duration of response was 12.5 months, and
the median progression-free survival was 11 months. Similar response rates were
observed across all subtypes of indolent non-Hodgkin’s lymphoma, though the numbers were small for some categories. The most common adverse events of grade 3 or
higher were neutropenia (in 27% of the patients), elevations in aminotransferase
levels (in 13%), diarrhea (in 13%), and pneumonia (in 7%).
Conclusions

In this single-group study, idelalisib showed antitumor activity with an acceptable
safety profile in patients with indolent non-Hodgkin’s lymphoma who had received
extensive prior treatment. (Funded by Gilead Sciences and others; ClinicalTrials.gov
number, NCT01282424.)
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I

ndolent non-Hodgkin’s lymphomas
constitute approximately one third of all cases
of non-Hodgkin’s lymphoma and include follicular lymphoma, small lymphocytic lymphoma,
marginal-zone lymphoma, and lymphoplasmacytic
lymphoma with or without Waldenström’s macroglobulinemia.1-3 It was estimated that approximately 20,000 people in the United States were
diagnosed with indolent non-Hodgkin’s lymphoma in 2012 and that approximately 7000 died of
this disease.4,5
The mainstay of treatment for indolent nonHodgkin’s lymphoma is an anti-CD20 antibody
(primarily rituximab) in combination with chemotherapy consisting of alkylating agents, anthracyclines, antimitotic agents, or purine analogues.
Although the current treatments for indolent nonHodgkin’s lymphomas are initially effective in inducing responses in most patients, they are not
curative and show decreasing efficacy with repeated administrations. In addition, chemotherapybased regimens are associated with long-term
toxic effects, including cumulative myelosuppression, neuropathy, cardiac toxicity, and secondary
cancers.6-9
The most recent chemotherapeutic agent that
has been approved by the Food and Drug Administration for use in patients with rituximab-
refractory indolent non-Hodgkin’s lymphoma is
the alkylating agent bendamustine,10 which has
become an important therapeutic option, although
it is not curative. Radioimmunotherapies,11 such
as iodine-131 (131I)–labeled tositumomab12 and
yttrium-90 (90Y)–labeled ibritumomab,13 can be
active, but owing to the potential for hematologic toxic effects, their use has been limited to
patients with adequate marrow function and limited marrow involvement by tumor. The use of
these agents is further constrained by the complex
procedures for their administration. For these
reasons, 90Y-ibritumomab is used infrequently,
and 131I-tositumomab has been withdrawn from
the market.14 There is an unmet need for new
treatments with novel mechanisms of action to
offer therapeutic options for patients with rituximab- and chemotherapy-refractory disease.
Phosphatidylinositol 3-kinase (PI3K) is a lipid
kinase that has a catalytic subunit with four different isoforms: α, β, γ, and δ. Activation of PI3K
generates phospholipid second messengers at
the cell membrane that recruit and activate multiple intracellular enzymes that are regulators of
cell proliferation, survival, and motility.15,16 The
n engl j med 370;11

α and β isoforms are widely expressed in many
tissues, whereas the γ and δ isoforms are highly
restricted to hematopoietic cells. In B lymphocytes,
the δ isoform (PI3Kδ) plays a central role in normal B-cell development and function, transducing
signals from the B-cell receptor as well as from
receptors for various cytokines, chemokines, and
integrins.17,18 PI3Kδ signaling pathways are frequently hyperactive in B-cell cancers,19-21 making
inhibition of PI3Kδ a promising target for the
therapy of indolent non-Hodgkin’s lymphoma.
Idelalisib is a potent, small-molecule inhibitor
of PI3Kδ that is highly selective for the δ isoform,
as compared with the α, β, and γ isoforms.19 In
lymphoid cell lines and primary samples from
patients, idelalisib blocked PI3Kδ-AKT signaling
and promoted apoptosis.19-21 Phase 1 studies involving patients with hematologic cancers showed
that idelalisib had an acceptable safety profile
and promising antitumor activity in patients with
indolent non-Hodgkin’s lymphoma22 and chronic
lymphocytic leukemia23 and established an idelalisib dose.
On the basis of these data, we hypothesized
that continuous treatment with idelalisib could
yield clinical benefit in patients with relapsed
indolent non-Hodgkin’s lymphoma. Our objectives
in this multicenter, phase 2, interventional, single-group study were to characterize the clinical
activity and safety of the drug in a group of patients with indolent non-Hodgkin’s lymphomas
who had received previous treatment with rituximab and an alkylating agent.

Me thods
Patients

Eligible patients had a confirmed diagnosis of
B-cell indolent non-Hodgkin’s lymphoma without
evidence of histologic transformation, according
to the criteria in the World Health Organization
2008 classification. Histologic types included
follicular lymphoma grade 1, 2, or 3a; small lymphocytic lymphoma; splenic, nodal, or extranodal marginal-zone lymphoma; or lymphoplasmacytic lymphoma with or without Waldenström’s
macroglobulinemia.3 In addition, eligible patients
had radiographically measurable disease (defined
as the presence of ≥1 lymph nodes with perpendicular dimensions measuring ≥2.0 × ≥1.0 cm)
and had received at least two prior systemic therapies for indolent non-Hodgkin’s lymphoma. Eligible patients met the criteria for refractoriness to
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both rituximab and an alkylating agent, whether
administered together or in successive treatment
regimens. Refractoriness was defined per protocol as less than a partial response or progression
of disease within 6 months after completion of a
prior therapy. Other major eligibility criteria included an age of at least 18 years, a Karnofsky
performance score24 of 60 or higher (on a scale
from 0 to 100, with 0 indicating death, 100 indicating the complete absence of symptoms, and
lower numbers indicating greater tumor-related
disability), the absence of active central nervous
system lymphoma, no prior history of hepatic
dysfunction, no active systemic infections (human immunodeficiency virus, hepatitis B virus,
or hepatitis C virus), and an absolute neutrophil
count of 1.0×109 per liter or higher and a platelet
count of 50×109 per liter or higher.

of

m e dic i n e

Study Design

We conducted Study 101-09 (also known as DELTA),
a single-group, open-label, phase 2 study, at 41
sites in the United States and Europe. Patients
with previously treated indolent non-Hodgkin’s
lymphoma that was refractory (as defined above)
to both rituximab and chemotherapy that included an alkylating agent received idelalisib, administered orally at a dose of 150 mg twice daily,
until the disease progressed, unacceptable toxic
effects developed, or the patient died. All patients
provided written informed consent.
Study Oversight

The main sponsor of the study was Gilead Sciences.
All the authors and the sponsors were responsible for designing the study protocol, amendments, and analysis plan. The authors, collabora-

Table 1. Baseline Characteristics of the Patients, Prior Therapy, and Treatment Disposition.*
Patients
(N = 125)

Characteristic
Age — yr
Median

64

Range

33–87

Male sex — no. (%)

80 (64)

Subtype of indolent non-Hodgkin’s lymphoma — no. (%)
Follicular lymphoma

72 (58)

Small lymphocytic lymphoma

28 (22)

Marginal-zone lymphoma

15 (12)

Lymphoplasmacytic lymphoma with or without Waldenström’s macroglobulinemia

10 (8)

Disease status — no. (%)
Stage III or IV

111 (89)

Elevated LDH

38 (30)

Bulky disease†

33 (26)

Baseline cytopenia — no. (%)‡
Neutropenia

17 (14)

Anemia

19 (15)

Thrombocytopenia

10 (8)

No. of prior regimens
Median

4

Range

2–12

Prior therapy — no. (%)

1010

Rituximab

125 (100)

Alkylating agent

125 (100)

Combination of rituximab and alkylating agent

114 (91)

Bendamustine

81 (65)

Anthracycline

79 (63)

Purine analogue

42 (34)

Stem-cell transplantation

14 (11)
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Table 1. (Continued.)
Patients
(N = 125)

Characteristic
Prior therapy to which the disease was refractory — no./total no. (%)
Rituximab

125/125 (100)

Alkylating agent

124/125 (99)§

Combined alkylator and rituximab

108/114 (95)

Bendamustine–rituximab

47/60 (78)

R-CHOP

40/56 (71)

R-CVP

29/36 (81)

Bendamustine

61/81 (75)

Disease refractory to ≥2 regimens

99/125 (79)

Disease refractory to most recent regimen

112/125 (90)

Duration of idelalisib therapy — mo
Median

6.6

Range

0.6–23.9

Treatment disposition — no. (%)
Ongoing

40 (32)

Discontinued

85 (68)

Progressive disease

41 (33)

Adverse event

25 (20)

Death

8 (6)

Investigator request

7 (6)

Withdrew consent

4 (3)

* LDH denotes lactate dehydrogenase, R-CHOP rituximab–cyclophosphamide–doxorubicin–prednisone, and R-CVP rituximab–cyclophosphamide–prednisone.
† Bulky disease was defined as the presence of one or more nodes with at least one dimension of 7 cm or more.
‡ Neutropenia was defined as an absolute neutrophil count of less than 1500 per cubic millimeter, anemia as a hemoglobin level of less than 10 g per deciliter, and thrombocytopenia as a platelet count of less than 75,000 per cubic
millimeter.
§ Refractoriness to two cycles was required to meet the criteria for alkylator-refractory disease. One patient received only
one cycle of chemotherapy, with no response after that cycle.

tors, and their research teams collected all the
data, and the sponsors confirmed the accuracy of
the data and compiled the data for summation
and analysis. The first draft of the manuscript
was written by the first (academic) author and by
an author who is employed by Gilead Sciences.
All the authors had full access to the data and
analyses for compilation of this report, reviewed
and edited the manuscript, vouch for the completeness and accuracy of the data and analysis
and for adherence of this report to the study protocol, and made the decision to submit the manuscript for publication. An institutional review
board or independent ethics committee at each
participating site approved the protocol (available with the full text of this article at NEJM.org).
The study was conducted according to principles
of the Declaration of Helsinki and the Internan engl j med 370;11

tional Conference on Harmonization Guidelines
for Good Clinical Practice.
Assessments

The primary end point was the overall rate of
response, with complete response and partial response assessed with the use of standard criteria
for lymphoma25 and for Waldenström’s macroglobulinemia.26 Responses were assessed by an
independent review committee. Patients with inadequate data for an assessment of response were
considered in the analysis of response rate as not
having had a response to treatment. Secondary
efficacy end points included the time to a response,
the duration of a response (measured from the
onset of response to disease progression), progression-free survival, and overall survival.
Adverse events and laboratory abnormalities
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that occurred during treatment were defined as
those that began or worsened in the period from
administration of the first dose of the study drug
to 30 days after administration of the last dose.
Events and abnormalities were graded according
to the Common Terminology Criteria for Adverse
Events, version 4.03.27
Patients were clinically evaluated at 2-week
intervals during the first 12 weeks of treatment,
at 4-week intervals from week 12 to week 24 of
treatment, at 6-week intervals from week 24 to
week 48 of treatment, and at 12-week intervals
thereafter. All visits included evaluations of vital
signs, adverse events, and concomitant medications. Tumor response and progression were
evaluated by means of computed tomography,
laboratory testing, and physical examination at
screening and at weeks 8, 16, 24, 36, and 48 and
every 12 weeks thereafter. Responses and disease progression were rigorously evaluated for
each patient by an independent review committee that consisted of three board-certified radiologists (two readers and one adjudicator) and
one board-certified oncologist–hematologist.
Statistical Analysis

The study used Simon’s two-stage design28 and
with a sample of at least 100 patients had a power of more than 90% to test the hypothesis that
the response rate would be 39% or higher against
the null hypothesis that it would be 20% or lower,
at a one-sided significance level of 0.005. Response
rates, exact binomial 95% confidence intervals,
and P values (based on the exact binomial test)
were calculated. Secondary end points of the duration of response and progression-free survival
were summarized with the use of the Kaplan–
Meier method. The date of progression was the
date on which progression was first identified
objectively. Death occurring within 30 days after
discontinuation of the study drug was considered
to be an event in the calculations of response and
progression-free survival. Data from patients
with nonprogressing disease were censored on
the date of the last tumor assessment.

R e sult s

m e dic i n e

line characteristics of the patients. The median
age of the patients was 64 years; 64% were male,
and 89% were white. Most of the patients (89%)
had stage III or IV indolent non-Hodgkin’s lymphoma, 30% had elevated lactate dehydrogenase
levels, 26% had lesions that were 7 cm or more in
at least one dimension, 15% had a hemoglobin
level of less than 10 g per deciliter, 14% had a
neutrophil count of less than 1500 per cubic millimeter, and 8% had a platelet count of less than
75,000 per cubic millimeter. Of the patients with
follicular lymphoma, 79% had scores on the follicular lymphoma International Prognostic Index
that indicated intermediate risk or high risk, and
17% had grade 3a disease (follicular large-cleavedcell lymphoma).
Patients had received a median of 4 prior regimens (range, 2 to 12), with 73 patients (58%) having received 4 or more prior regimens. Among
alkylating agents, cyclophosphamide had been
administered to 111 patients (89%) and bendamustine to 81 patients (65%). The most common
prior regimens included bendamustine–rituximab
(60 patients [48%]), rituximab–cyclophosphamide–doxorubicin–prednisone (R-CHOP) (56 patients [45%]), rituximab monotherapy (50 patients
[40%]), and rituximab–cyclophosphamide–prednisone (R-CVP) (36 patients [29%]). Fourteen patients (11%) had received prior high-dose chemotherapy and had undergone autologous stem-cell
transplantation.
All the patients had disease that was refractory (as defined above) to rituximab, and 124
patients (99%) had disease that was refractory to
an alkylating agent; in 108 patients (86%), the
disease was refractory to combination therapy
with an alkylating agent and rituximab. A total
of 99 patients (79%) had disease that was refractory to two or more prior regimens. Among patients who had received prior regimens consisting of bendamustine plus rituximab, R-CHOP, or
R-CVP, 78%, 71%, and 81%, respectively, had disease that was refractory to those therapies. A total of 112 patients (90%) had disease that was
refractory to the last therapy they had received
immediately before idelalisib.
Efficacy

Patient Characteristics

Between April 2011 and October 2012, we enrolled 125 patients with relapsed indolent nonHodgkin’s lymphoma. The date of data cutoff
was June 25, 2013. Table 1 summarizes the base1012
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A waterfall plot of the best overall response with
respect to tumor size shows that 110 of 122 patients who could be evaluated (90%) had a reduction in the size of lymph nodes during treatment
(Fig. 1). On the basis of assessment by the inde-
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2 Patients had
no baseline
evaluation

75

SPD of Measured Lymph Nodes
(best % change from baseline)

50

1 Patient had
disease progression on the basis
of lymph node
biopsy, no baseline evaluation

25
0

FL (N=72)
SLL ( N=28)

−25

MZL (N=15)
LPL/WM (N=10)

−50
−75
−100

Individual Patients (N=125)

Figure 1. Best Overall Response.
The best response with respect to tumor size during idelalisib treatment, according to assessment by an independent review committee, is shown for the 125 patients in the study. Among the 122 patients with measurable lesions
both at baseline and after baseline, 110 patients (90%) had improvements in lymphadenopathy, as assessed by
changes in the sums of the products of the perpendicular dimensions (SPD) of index lesions. The dashed line shows
the percentage change that represents the criterion for lymphadenopathy response, according to Cheson et al.25
FL denotes follicular lymphoma, LPL/WM lymphoplasmacytic lymphoma with or without Waldenström’s macroglobulinemia, MZL marginal-zone lymphoma, and SLL small lymphocytic lymphoma.

pendent review committee, the response rate was
57% (95% confidence interval, 48 to 66), with 71
responses in 125 patients. A total of 7 patients
(6%) had a complete response, 63 patients (50%)
had a partial response, and 1 patient (1%) with
Waldenström’s macroglobulinemia had a minor
response. There was a high degree of concordance
between the assessments of response by the independent review committee and the assessments by the investigators, with 85% agreement
with respect to overall response (Table S1 in the
Supplementary Appendix, available at NEJM.org).
The rates of response were consistent across subgroups, with favorable response rates observed
regardless of the number of prior regimens, refractoriness of the disease to the most recent
prior therapy, refractoriness to bendamustine, disease subtype, bulky disease status, age, and sex
(Fig. 2). The response rates ranged from 47 to
80% in various subgroups. There was no correlation of efficacy with pharmacokinetic measures
(Fig. S2 in the Supplementary Appendix).
Responses were rapid and durable with continued administration of idelalisib. The median
time to a response was 1.9 months (range, 1.6 to
8.3) (Fig. 3A). The median duration of response
was 12.5 months (range, 0.03 to 14.8) (Fig. 3B),
n engl j med 370;11

exceeding the median duration of response (5.9
months) in the group of 28 patients who had
had a response to the most recent therapy before
idelalisib. The median progression-free survival
was 11.0 months (range, 0.03 to 16.6) (Fig. 3C),
with 47% of the patients remaining progressionfree at 48 weeks. At the time of data cutoff, the
median overall survival was 20.3 months (range,
0.7 to 22.0) (Fig. 3D), and overall survival at 1 year
was estimated to be 80%. The median follow-up
time was 9.7 months.
Safety Profile

The median duration of treatment with idelalisib
was 6.6 months (range, 0.6 to 23.9), and the mean
(±SD) duration was 8.1±5.7 months. At the time
of the data cutoff, 108 patients (86%) had received
idelalisib at a dose of 150 mg twice daily for at
least 2 months, and 68 patients (54%) had received the drug for at least 6 months; treatment
was ongoing for 40 patients (32%). The incidence
rates of adverse events occurring during treatment
in 10% or more of the patients are listed in Table
2. The following events (all grades) occurred in
more than 20% of patients: diarrhea (in 43%),
fatigue (in 30%), nausea (in 30%), cough (in 29%),
and pyrexia (in 28%). The most frequently re-
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Subgroup
Overall
Age
<65 yr
≥65 yr
Sex
Male
Female
Lymphoma subtype
FL
SLL
MZL
LPL/WM
Bulky disease
No (LD <7 cm)
Yes (LD ≥7 cm)
No. of previous therapies
<4
≥4
Previous bendamustine use
No
Yes
Refractory to bendamustine
No
Yes
Refractory to last therapy
No
Yes

n e w e ng l a n d j o u r na l

No. of
Patients

of

m e dic i n e

Overall Response Rate (95% CI)

125

0.57 (0.48–0.66)

69
56

0.57 (0.44–0.68)
0.57 (0.43–0.70)

80
45

0.55 (0.44–0.66)
0.60 (0.44–0.74)

72
28
15
10

0.54 (0.42–0.66)
0.61 (0.41–0.79)
0.47 (0.21–0.73)
0.80 (0.44–0.98)

92
33

0.57 (0.46–0.67)
0.58 (0.39–0.75)

52
73

0.50 (0.36–0.64)
0.62 (0.50–0.73)

44
81

0.57 (0.41–0.72)
0.57 (0.45–0.68)

20
61

0.50 (0.27–0.73)
0.59 (0.46–0.71)

13
112

0.69 (0.39–0.91)
0.55 (0.46–0.65)
0.0

0.2

0.4

0.6

0.8

1.0

Overall Response Rate

Figure 2. Forest Plot of Overall Response Rate.
A forest plot is shown of the overall response rate, in the total cohort and according to subgroups, among patients
with refractory indolent non-Hodgkin’s lymphoma. The response rate was assessed by an independent review committee. The dashed line shows the null hypothesis response rate of 20%. LD denotes longest diameter.

ported adverse events of grade 3 or higher were
diarrhea (in 13% of the patients), pneumonia (in
7%), and dyspnea (in 3%). The most common
laboratory abnormalities of grade 3 or higher
that occurred during treatment (Table 2) included neutropenia (in 27% of the patients) and elevations in levels of serum alanine or aspartate
aminotransferase (in 13%). Other cytopenias of
grade 3 or higher included thrombocytopenia (in
6% of the patients) and anemia (in 2%). Changes
in blood counts during therapy are described in
Table S1 in the Supplementary Appendix. There
were no significant changes in immunoglobulin
levels or T-lymphocyte subsets.
Adverse events led to discontinuation of idel
alisib in 25 patients. These adverse events included elevations in levels of serum alanine or
aspartate aminotransferase in 5 patients (4%),
1014
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colitis in 4 patients (3%), pneumonia and pneumonitis in 3 patients each (2%), and diarrhea and
neutropenia in 2 patients each (2%). The initial
dose of 150 mg twice daily was reduced to 100 mg
twice daily or to 75 mg twice daily in 42 patients
(34%). The adverse events that led most frequently to dose reduction were elevations in
levels of serum alanine or aspartate aminotransferase, followed by diarrhea and neutropenia. The
most common serious adverse events included
pyrexia in 13 patients (10%), pneumonia and diarrhea in 9 patients each (7%), colitis in 5 patients (4%), dehydration and febrile neutropenia
in 4 patients each (3%), and acute renal failure
and pneumonitis in 3 patients each (2%).
Grade 3 or higher diarrhea, colitis, or both
developed in 20 patients (16%), at a median of
6 months after the initiation of treatment (range,
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A Time to Response

B Duration of Response
100

Percent with Continued Response

Percent with Response

100

75
Median, 1.9 mo
(N=71)

50

25

0

0

2

4

6

8

75
Median, 12.5 mo
(N=71)

50

25

0

10

0

3

6

Months from Start of Idelalisib
No. at Risk

40

59

66

No. at Risk

68

71

100

75

75

Median, 11 mo
(N=125)

50

25

0

3

54

100

34

17

15

18

0

0

9

6

9

12

15

18

13

0

Median, 20.3 mo
(N=125)

50

25

0

0

3

Months from Start of Idelalisib
No. at Risk 125

12

D Overall Survival

100

Percent Surviving

Percent with Progression-free
Survival

C Progression-free Survival

0

9

Months from Response

59

39

20

6

9

12

15

18

21

24

4

0

Months from Start of Idelalisib
No. at Risk 125

118

105

68

38

23

12

Figure 3. Kaplan–Meier Curves for Secondary End Points.
Kaplan–Meier curves are shown for the secondary end points of the time to response (Panel A), the duration of response (Panel B), progression-free survival (Panel C), and overall survival (Panel D) among patients with refractory indolent non-Hodgkin’s lymphoma who
were treated with idelalisib (intention-to-treat population). The end points were assessed by an independent review committee.

1 to 13); of these, 6 cases resolved spontaneously
or after dose reduction, 6 cases (2 in patients
with progressive disease) led to permanent discontinuation of idelalisib, and 8 cases resolved
with a temporary interruption of the drug. Of
the 8 patients in whom the drug was temporarily interrupted, 5 were able to resume therapy
without a recurrence of toxic effects.
In all patients with grade 1 or 2 elevations in
levels of serum alanine or aspartate aminotransferase, the levels returned to values within normal
ranges despite the fact that the patients continued taking the drug. Grade 3 or higher elevations
of serum aminotransferase levels developed in
16 patients (13%), at a median of 6.3 weeks after
the initiation of treatment (range, 4 to 11). These
cases were asymptomatic and after interruption
n engl j med 370;11

of idelalisib therapy, all resolved to grade 1 or less
within a median of 3.9 weeks (range, 1 to 6).
Fourteen patients were rechallenged, 10 of whom
(71%) were successfully able to continue therapy
with a temporary dose reduction and subsequent
reescalation.
A total of 28 deaths (22%) were reported.
Eleven deaths occurred while the patient was receiving the study drug or within 30 days after
the last dose. The causes of death were progressive disease (3 patients), pneumonia (3 patients),
and cardiac arrest, cardiac failure, splenic infarction, septic shock, and pneumonitis (1 patient
each). The remaining 17 deaths, due predominantly to progressive disease, occurred during
long-term follow-up. No evidence of cumulative
toxic effects was documented.
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The

n e w e ng l a n d j o u r na l

Discussion
In this noncomparative trial, idelalisib showed
antitumor activity in patients with indolent nonHodgkin’s lymphoma that had become refractory
to both rituximab and alkylating agents. Idela
lisib monotherapy resulted in tumor reductions in
Table 2. Adverse Events during Treatment.*
Event or Abnormality

Grade
Any

≥3
no. (%)

Adverse event

103 (82)

68 (54)

Diarrhea

54 (43)

16 (13)

Nausea

37 (30)

2 (2)
2 (2)

Fatigue

37 (30)

Cough

36 (29)

0

Pyrexia

35 (28)

2 (2)

Decreased appetite

22 (18)

1 (1)

Dyspnea

22 (18)

4 (3)

Abdominal pain

20 (16)

3 (2)

Vomiting

19 (15)

3 (2)

Upper respiratory tract infection

18 (14)

0

Weight decreased

17 (14)

0

Rash

16 (13)

2 (2)

Asthenia

14 (11)

3 (2)

Night sweats

14 (11)

0

Pneumonia

14 (11)

9 (7)

Peripheral edema

13 (10)

3 (2)

Headache

13 (10)

1 (1)

Hematopoietic laboratory abnormality
Decreased neutrophils

70 (56)

34 (27)

Decreased hemoglobin

35 (28)

2 (2)

Decreased platelets

32 (26)

8 (6)

Chemical laboratory abnormality
Increased ALT

59 (47)

16 (13)

Increased AST

44 (35)

10 (8)

Increased alkaline phosphatase

28 (22)

0

Increased bilirubin

13 (10)

0

* Included are adverse events and selected laboratory abnormalities that occurred during treatment in 10% or more of the 125 patients in the study,
regardless of whether the event was related to the study drug. Adverse events
that occurred during treatment are classified according to the preferred term
in the Medical Dictionary for Regulatory Activities (MedDRA), version 15.1.
Patients who had multiple events within the same preferred-term category
were counted once in that category. ALT denotes alanine aminotransferase,
and AST aspartate aminotransferase.
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90% of the patients, with 57% meeting the criteria for an objective tumor response. Disease control could be protracted: the median duration of
response was 12.5 months, and the median progression-free survival was 11.0 months. Objective
responses were observed in patients with follicular lymphoma and small lymphocytic lymphoma,
as well as in patients with the rarer subsets of
indolent non-Hodgkin’s lymphoma — marginalzone lymphoma and lymphoplasmacytic lymphoma with or without Waldenström’s macroglobulinemia. Thus, therapeutic targeting of the PI3Kδ
pathway may be clinically relevant in all these
B-cell cancers.
The value of this regimen included a favorable
toxicity profile, with low rates of discontinuation
due to toxic effects and a low incidence of severe
adverse events. Though serum elevations in hepatic aminotransferase levels were observed in
47% of patients, elevations of grade 3 or higher
occurred in 13% of patients, were reversible in
all patients, and resulted in discontinuation of
treatment in only 5 patients (4%). Grade 3 or
higher diarrhea or colitis occurred in 13% and 4%
of the patients, respectively, and could often be
managed with interruptions in drug treatment or
adjustments of the dose.
Clinically significant hematologic toxic effects
were also uncommon. Since we designed the trial
for a patient population that had received extensive prior treatment, we specifically allowed the
use of red-cell and platelet transfusions as well
as neutrophil growth factors to meet the protocolrequired baseline eligibility thresholds for patients with impaired marrow reserve or extensive
tumor infiltration. In this context, the 27% rate
of neutropenia of grade 3 or higher was not considered to be excessive, and febrile neutropenia
was a rare event, occurring in 4 patients (3%).
The results with idelalisib are similar to
those observed in evaluations of other cytotoxic
and noncytotoxic agents in previously treated
patients. 131I-tositumomab and 90Y-ibritumomab,
when studied in rituximab-refractory follicular
lymphoma, yielded response rates of 62 to 74% and
progression-free survival of 6.8 to 8.8 months.29,30
The alkylating agent bendamustine was approved
for the treatment of indolent non-Hodgkin’s lymphoma that is refractory to rituximab, on the
basis of a response rate of 75% and a median
duration of response of 9.2 months in a cohort
of patients who had received a median of two
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prior regimens.31 A 30-patient subgroup from
the bendamustine trial,31 comprising patients with
alkylator-refractory disease, had a response rate
of 64% and median progression-free survival of
7.5 months. The majority of patients treated with
idelalisib in the current trial had received prior
therapy with bendamustine. Other noncytotoxic
agents, such as bortezomib,32 fostamatinib,33
ibrutinib,34 and lenalidomide,35 have been associated with response rates of 12 to 52% in populations that received less extensive prior therapy
than did those taking idelalisib in this study.
In conclusion, in this uncontrolled trial, idel
alisib targets the PI3Kδ pathway and appears to
provide effective oral monotherapy in patients
with previously treated indolent non-Hodgkin’s

lymphoma. The toxicity profile does not generally overlap with that of most other active agents
and may allow the development of more highly
active combination regimens.
Sponsored by Gilead Sciences and Calistoga Pharmaceuticals (which was acquired by Gilead Sciences in 2011), by a Fred
Hutchinson Cancer Research Center–University of Washington
Cancer Consortium Cancer Center Support Grant of the National Institutes of Health (P30 CA015704), and by philanthropic gifts from Frank and Betty Vandermeer. Dr. Gopal is a
Scholar in Clinical Research for the Leukemia and Lymphoma
Society.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
We thank the patients for their dedication to this clinical trial
and the clinical personnel at each of the study sites for their
diligence in caring for patients and collecting study data, as well
as the study team members at INC Research, Raleigh, NC, for
overseeing the administration of the trial.

APPENDIX
The authors’ affiliations are as follows: the Division of Medical Oncology, University of Washington School of Medicine (A.K.G.), the
Clinical Research Division, Fred Hutchinson Cancer Research Center (A.K.G.), and Clinical Development, Oncology, Gilead Sciences
(D.J., L.L.M., L.H., D.L., R.D.D., W.R.G.) — all in Seattle; Hematology Clinic, University of Wisconsin Carbone Cancer Center, Madison
(B.S.K.); the Division of Hematology–Oncology, David Geffen School of Medicine at UCLA, Los Angeles (S.V.); the Department of
Medicine, Washington University School of Medicine, St. Louis (N.D.W.-J.); Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia (S.J.S.); the Department of Hematology, Jagiellonian University, Krakow, Poland (W.J.J.); Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville (I.W.F.); the Department of Hematology and Medical
Oncology, Winship Cancer Institute of Emory University, Atlanta (C.R.F.); the Division of Hematology–Oncology, Weill Cornell Medical
College, New York (P.M.); the Department of Internal Medicine, University Hospital of Ulm, Ulm (A.V.), and the Department of Internal
Medicine, University Hospital Grosshadern, LMU, Munich (M.D.) — both in Germany; the Division of Hematology, Ohio State University Wexner Medical Center, Columbus (K.A.B.); the Division of Lymphoma, John Theurer Cancer Center at Hackensack University
Medical Center, Hackensack, NJ (A.H.G.); Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom (A.J.D.);
Institute of Hematology and Oncology, University of Bologna, Bologna, Italy (P.L.Z.); and Hospices Civils de Lyon, University Claude
Bernard, Hematology Department, Pierre Benite, France (G.A.S.).
References
1. Shankland KR, Armitage JO, Hancock

BW. Non-Hodgkin lymphoma. Lancet 2012;
380:848-57.
2. Horning SJ. Natural history of and
therapy for the indolent non-Hodgkin’s
lymphomas. Semin Oncol 1993;20:Suppl 5:
75-88.
3. Swerdlow S, Campo E, Harris NL, et
al., eds. WHO classification of tumours
of haematopoietic and lymphoid tissues.
4th ed. Lyon, France: IARC Press, 2008.
4. Siegel R, Naishadham D, Jemal A.
Cancer statistics, 2012. CA Cancer J Clin
2012;62:10-29.
5. National Cancer Institute. Estimated
new cancer causes and deaths for 2013.
Bethesda, MD: National Institutes of
Health, 2013 (http://seer.cancer.gov/csr/
1975_2010/results_single/sect_01_table.01
.pdf).
6. Lunning MA, Vose JM. Management
of indolent lymphoma: where are we now
and where are we going. Blood Rev 2012;
26:279-88.
7. Gribben JG. How I treat indolent lymphoma. Blood 2007;109:4617-26.
8. National Comprehensive Cancer Net-

work. Treatment guidelines for lymphoma.
2013 (http://www.nccn.org/professionals/
physician_gls/f_guidelines.asp).
9. Leonard JP, Gregory SA, Maloney DG,
Vose JM, Younes A, Zelenetz AD. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent nonHodgkin lymphoma. Clin Adv Hematol
Oncol 2008;6:437-45.
10. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol
2009;27:1492-501. [Erratum, J Clin Oncol
2009;27:2892.]
11. Tomblyn M. Radioimmunotherapy for
B-cell non-Hodgkin lymphomas. Cancer
Control 2012;19:196-203.
12. William BM, Bierman PJ. I-131 tositumomab. Expert Opin Biol Ther 2010;10:
1271-8.
13. Johnston PB, Bondly C, Micallef IN.
Ibritumomab tiuxetan for non-Hodgkin’s
lymphoma. Expert Rev Anticancer Ther
2006;6:861-9.
14. GSK to discontinue manufacture and
sale of the BEXXAR therapeutic regimen
(tositumomab and iodine I 131 tositumomab). GSK press release of Glaxo

n engl j med 370;11

nejm.org

SmithKline, Brentford, Middlesex, United
Kingdom, August 7, 2013.
15. Vanhaesebroeck B, Stephens L,
Hawkins P. PI3K signalling: the path to
discovery and understanding. Nat Rev
Mol Cell Biol 2012;13:195-203.
16. Vanhaesebroeck B, Guillermet-Guibert
J, Graupera M, Bilanges B. The emerging
mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:32941.
17. Durand CA, Hartvigsen K, Fogelstrand L, et al. Phosphoinositide 3-kinase
p110 delta regulates natural antibody production, marginal zone and B-1 B cell
function, and autoantibody responses.
J Immunol 2009;183:5673-84.
18. Bilancio A, Okkenhaug K, Camps M,
et al. Key role of the p110delta isoform of
PI3K in B-cell antigen and IL-4 receptor
signaling: comparative analysis of genetic
and pharmacologic interference with
p110delta function in B cells. Blood
2006;107:642-50.
19. Lannutti BJ, Meadows SA, Herman
SE, et al. CAL-101, a p110delta selective
phosphatidylinositol-3-kinase inhibitor

march 13, 2014

1017

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 9, 2014. For personal use only. No other uses without permission.
Copyright © 2014 Massachusetts Medical Society. All rights reserved.

PI3Kδ Inhibition by Idelalisib in Relapsed Indolent Lymphoma
for the treatment of B-cell malignancies,
inhibits PI3K signaling and cellular viability. Blood 2011;117:591-4.
20. Hoellenriegel J, Meadows SA, Sivina
M, et al. The phosphoinositide 3′-kinase
delta inhibitor, CAL-101, inhibits B-cell
receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Blood 2011;118:3603-12.
21. Herman SE, Lapalombella R, Gordon
AL, et al. The role of phosphatidylinositol
3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011;117:4323-7.
22. Benson DM, Kahl BS, Furman RR, et al.
Final results of a phase I study of idelalisib,
a selective inhibitor of PI3Kδ, in patients
with relapsed or refractory indolent nonHodgkin lymphoma (iNHL). J Clin Oncol
2013;31:Suppl:8526. abstract.
23. Brown JR, Furman RR, Flinn I, et al.
Final results of a phase I study of idelalisib
(GSE-1101) a selective inhibitor of PI3Kδ, in
patients with relapsed or refractory CLL.
J Clin Oncol 2013;31:Suppl:7003. abstract.
24. Schag CC, Heinrich RL, Ganz PA.
Karnofsky performance status revisited:
reliability, validity, and guidelines. J Clin
Oncol 1984;2:187-93.

1018

25. Cheson BD, Pfistner B, Juweid ME, et

al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:57986.
26. Owen RG, Kyle RA, Stone MJ, et al.
Response assessment in Waldenström
macroglobulinaemia: update from the
VIth International Workshop. Br J Haematol 2013;160:171-6.
27. Common Terminology Criteria for
Adverse Events v4.0 (CTCAE). Cancer
Therapy Evaluation Program, common
terminology for adverse events, version
30. Bethesda, MD: National Cancer Institute, 2009 (http://evs.nci.nih.gov/ftp1/
CTCAE/CTCAE_4.03_2010-06-14_
QuickReference_5x7.pdf).
28. Simon R. Optimal two-stage designs
for phase II clinical trials. Control Clin
Trials 1989;10:1-10.
29. Witzig TE, Flinn IW, Gordon LI,
et al. Treatment with ibritumomab ti
uxetan radioimmunotherapy in patients
with rituximab-refractory follicular nonHodgkin’s lymphoma. J Clin Oncol 2002;
20:3262-9.
30. Horning SJ, Younes A, Jain V, et al.
Efficacy and safety of tositumomab and
iodine-131 tositumomab (Bexxar) in B-cell

n engl j med 370;11

nejm.org

lymphoma, progressive after rituximab.
J Clin Oncol 2005;23:712-9.
31. Kahl BS, Bartlett NL, Leonard JP, et al.
Bendamustine is effective therapy in patients with rituximab-refractory, indolent
B-cell non-Hodgkin lymphoma: results
from a multicenter study. Cancer 2010;
116:106-14.
32. Di Bella N, Taetle R, Kolibaba K, et al.
Results of a phase 2 study of bortezomib
in patients with relapsed or refractory indolent lymphoma. Blood 2010;115:475-80.
33. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical
activity in non-Hodgkin lymphoma and
chronic lymphocytic leukemia. Blood 2010;
115:2578-85.
34. Advani RH, Buggy JJ, Sharman JP, et
al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity
in patients with relapsed/refractory B-cell
malignancies. J Clin Oncol 2013;31:88-94.
35. Witzig TE, Wiernik PH, Moore T, et
al. Lenalidomide oral monotherapy produces durable responses in relapsed or
refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol 2009;27:5404-9.
Copyright © 2014 Massachusetts Medical Society.

march 13, 2014

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 9, 2014. For personal use only. No other uses without permission.
Copyright © 2014 Massachusetts Medical Society. All rights reserved.

